{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(1)"],"submitter":["Rocha MAD"],"pubmed_abstract":["Adult female acne is a chronic inflammatory, immune-mediated disease that affects the pilosebaceous unit in women in their 20s to 40s, and is considered different from acne vulgaris. <i>Propionibacterium acnes</i> is recognized by TLR-2, resulting in activation of this receptor and an inflammatory response through the <i>NFκ</i> B pathway. This therapeutic, interventional, open, randomized, evaluator-blinded and comparative trial included 38 adult women with moderate facial acne and 10 age-matched controls, all aged between 26 and 44 years. Two treatments were performed over six months: 15% azelaic acid gel (AA) bid (n = 18) and oral contraceptive (COC) drospirenone 3 mg/ethinylestradiol .02 mg (n = 20). Biopsies were taken at baseline (control, lesion, perilesional) and at the conclusion (lesion and perilesional) of the study to evaluate TLR-2 expression by immunohistochemistry. Lesion count and blind photographic evaluation were used for efficacy. The groups were homogeneous: 70% of lesions were located in the submandibular area, 95% of participants had inflammatory lesions; of these, 50% had persistent and 50% had late-onset acne. The mean ages were 33.7 ± 5.5 and 33.1 ± 5.3 years (COC and AA group, respectively). A moderate clinical improvement was observed in both groups. No difference in TLR-2 expression in the lesion or perilesional areas was observed; however, reduced TLR-2 expression was seen in the control group. A significant reduction in expression was observed after both treatments, with no difference between the groups. This finding suggests an anti-inflammatory effect of COCs and AA in adult female acne, via modulation of the TLR-2 receptor."],"journal":["Dermato-endocrinology"],"pagination":["e1361570"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5821154"],"repository":["biostudies-literature"],"pubmed_title":["Modulation of Toll Like Receptor-2 on sebaceous gland by the treatment of adult female acne."],"pmcid":["PMC5821154"],"pubmed_authors":["Sanudo A","Bagatin E","Guadanhim LRS","Rocha MAD"],"additional_accession":[]},"is_claimable":false,"name":"Modulation of Toll Like Receptor-2 on sebaceous gland by the treatment of adult female acne.","description":"Adult female acne is a chronic inflammatory, immune-mediated disease that affects the pilosebaceous unit in women in their 20s to 40s, and is considered different from acne vulgaris. <i>Propionibacterium acnes</i> is recognized by TLR-2, resulting in activation of this receptor and an inflammatory response through the <i>NFκ</i> B pathway. This therapeutic, interventional, open, randomized, evaluator-blinded and comparative trial included 38 adult women with moderate facial acne and 10 age-matched controls, all aged between 26 and 44 years. Two treatments were performed over six months: 15% azelaic acid gel (AA) bid (n = 18) and oral contraceptive (COC) drospirenone 3 mg/ethinylestradiol .02 mg (n = 20). Biopsies were taken at baseline (control, lesion, perilesional) and at the conclusion (lesion and perilesional) of the study to evaluate TLR-2 expression by immunohistochemistry. Lesion count and blind photographic evaluation were used for efficacy. The groups were homogeneous: 70% of lesions were located in the submandibular area, 95% of participants had inflammatory lesions; of these, 50% had persistent and 50% had late-onset acne. The mean ages were 33.7 ± 5.5 and 33.1 ± 5.3 years (COC and AA group, respectively). A moderate clinical improvement was observed in both groups. No difference in TLR-2 expression in the lesion or perilesional areas was observed; however, reduced TLR-2 expression was seen in the control group. A significant reduction in expression was observed after both treatments, with no difference between the groups. This finding suggests an anti-inflammatory effect of COCs and AA in adult female acne, via modulation of the TLR-2 receptor.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2024-11-07T04:49:33.349Z","creation":"2019-03-26T23:04:37Z"},"accession":"S-EPMC5821154","cross_references":{"pubmed":["29484093"],"doi":["10.1080/19381980.2017.1361570"]}}